EPS for Argonaut Gold Inc. (AR) Expected At $0.05; Corcept Therapeutics (CORT) SI Increased By 7.1%

April 20, 2018 - By Russell Anderson

Corcept Therapeutics Incorporated (NASDAQ:CORT) Logo

Corcept Therapeutics Incorporated (NASDAQ:CORT) had an increase of 7.1% in short interest. CORT’s SI was 17.23M shares in April as released by FINRA. Its up 7.1% from 16.09M shares previously. With 1.72M avg volume, 10 days are for Corcept Therapeutics Incorporated (NASDAQ:CORT)’s short sellers to cover CORT’s short positions. The SI to Corcept Therapeutics Incorporated’s float is 16.69%. The stock decreased 2.37% or $0.43 during the last trading session, reaching $17.74. About 320,639 shares traded. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 52.11% since April 20, 2017 and is uptrending. It has outperformed by 40.56% the S&P500.

Analysts expect Argonaut Gold Inc. (TSE:AR) to report $0.05 EPS on May, 8.They anticipate $0.04 EPS change or 44.44% from last quarter’s $0.09 EPS. T_AR’s profit would be $8.88 million giving it 11.83 P/E if the $0.05 EPS is correct. After having $0.05 EPS previously, Argonaut Gold Inc.’s analysts see 0.00% EPS growth. The stock increased 0.21% or $0.005 during the last trading session, reaching $2.365. About 112,304 shares traded. Argonaut Gold Inc. (TSE:AR) has 0.00% since April 20, 2017 and is . It has underperformed by 11.55% the S&P500.

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company has market cap of $2.04 billion. It offers Korlym tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It has a 17.06 P/E ratio. The firm is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer.

Since December 8, 2017, it had 1 insider purchase, and 5 sales for $515,904 activity. FISHMAN ROBERT S sold $125,323 worth of Corcept Therapeutics Incorporated (NASDAQ:CORT) on Wednesday, March 7. $155,102 worth of Corcept Therapeutics Incorporated (NASDAQ:CORT) was bought by GALA RENEE D on Tuesday, March 6.

Investors sentiment decreased to 1.49 in 2017 Q4. Its down 0.47, from 1.96 in 2017Q3. It is negative, as 30 investors sold Corcept Therapeutics Incorporated shares while 42 reduced holdings. 40 funds opened positions while 67 raised stakes. 87.40 million shares or 21.46% more from 71.96 million shares in 2017Q3 were reported. Arizona State Retirement Systems reported 0.02% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT). Crow Point Ltd Liability holds 0.01% or 2,921 shares in its portfolio. Denali Ltd Com invested in 0.76% or 273,000 shares. Petrus Trust Lta holds 16,359 shares. Citigroup Inc holds 0% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 249,492 shares. Meeder Asset Management invested 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Alliancebernstein Limited Partnership stated it has 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Louisiana State Employees Retirement Systems stated it has 40,800 shares. Teachers Retirement System Of The State Of Kentucky stated it has 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Federated Invsts Pa invested 0.64% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Tiaa Cref Mngmt Limited Co, New York-based fund reported 475,858 shares. Raymond James Assoc has invested 0% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT). Manufacturers Life Ins The owns 236,728 shares. Sheets Smith Wealth owns 24,161 shares. Texas-based Texas Permanent School Fund has invested 0.01% in Corcept Therapeutics Incorporated (NASDAQ:CORT).

Among 7 analysts covering Corcept Therapeutics (NASDAQ:CORT), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Corcept Therapeutics had 11 analyst reports since February 2, 2017 according to SRatingsIntel. The company was maintained on Friday, September 8 by Piper Jaffray. On Friday, November 3 the stock rating was maintained by Stifel Nicolaus with “Buy”. On Tuesday, March 20 the stock rating was maintained by FBR Capital with “Buy”. The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) has “Buy” rating given on Thursday, August 24 by Piper Jaffray. The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) has “Buy” rating given on Thursday, March 8 by FBR Capital. The firm has “Buy” rating given on Friday, April 13 by Seaport Global. Ladenburg Thalmann initiated the shares of CORT in report on Thursday, February 2 with “Buy” rating. The rating was maintained by Piper Jaffray on Wednesday, October 11 with “Buy”.

Argonaut Gold Inc., a mining company, engages in the exploration, development, and production of gold and silver in North America. The company has market cap of $419.88 million. The company's principal assets include the El Castillo mine located in the State of Durango, Mexico; the La Colorada mine situated in the State of Sonora, Mexico; the San Antonio gold project located in the State of Baja California Sur, Mexico; the San Agustin project situated in the State of Durango, Mexico; and the Magino gold project located in the province of Ontario, Canada. It has a 17.14 P/E ratio.

Among 6 analysts covering Argonaut Gold Inc. (TSE:AR), 2 have Buy rating, 2 Sell and 2 Hold. Therefore 33% are positive. Argonaut Gold Inc. had 21 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was maintained by Scotia Capital on Friday, July 24 with “Outperform”. IBC maintained Argonaut Gold Inc. (TSE:AR) rating on Wednesday, August 19. IBC has “Sector Perform” rating and $3.50 target. On Tuesday, January 17 the stock rating was maintained by Scotia Capital with “Outperform”. The firm earned “Buy” rating on Tuesday, December 13 by Cormark Securities. The stock of Argonaut Gold Inc. (TSE:AR) earned “Outperform” rating by Scotia Capital on Friday, February 17. The firm has “Outperform” rating by Scotia Capital given on Friday, July 15. On Friday, December 8 the stock rating was maintained by Suntrust Robinson with “Hold”. The stock has “Market Perform” rating by BMO Capital Markets on Friday, July 15. The company was maintained on Friday, November 4 by Scotia Capital. The firm has “Outperform” rating by RBC Capital Markets given on Monday, August 24.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>